From: Aiming to increase birth weight: a randomised trial of pre-pregnancy information, advice and counselling in inner-urban Melbourne
PAPER SECTION And topic
Reported on Page #
TITLE & ABSTRACT
How participants were allocated to interventions (e.g., "random allocation", "randomized", or "randomly assigned").
Eligibility criteria for participants and the settings and locations where the data were collected
Precise details of the interventions intended for each group and how and when they were actually administered
Clearly defined primary and secondary outcome measures and, when applicable, any methods used to enhance the quality of measurements (e.g., multiple observations, training of assessors).
How sample size was determined and, when applicable, explanation of any interim analyses and stopping rules
Randomization – Sequence generation
Method used to generate the random allocation sequence, including details of any restrictions (e.g., blocking, stratification)
Randomization – Allocation concealment
Method used to implement the random allocation sequence (e.g., numbered containers or central telephone), clarifying whether the sequence was concealed until interventions were assigned.
Randomization – Implementation
Who generated the allocation sequence, who enrolled participants, and who assigned participants to their groups
Whether or not participants, those administering the interventions, and those assessing the outcomes were blinded to group assignment When relevant, how the success of blinding was evaluated
Statistical methods used to compare groups for primary outcome(s); Methods for additional analyses such as subgroup analyses and adjusted analyses.
RESULTS Participant flow
Flow of participants through each stage (a diagram is strongly recommended). Specifically, for each group report the numbers of participants randomly assigned, receiving intended treatment, completing the study protocol, and analyzed for the primary outcome. Describe protocol deviations from study as planned, together with reasons n/a
7, 22, Table 1
Baseline demographic and clinical characteristics of each group
6, Table 2
Number of participants (denominator) in each group included in each analysis and whether the analysis was by "intention-to-treat" State the results in absolute numbers when feasible (e.g., 10/20, not 50%).
392 and 394, I-T-T
Outcomes and estimation
For each primary and secondary outcome, a summary of results for each group, and the estimated effect size and its precision (e.g., 95% confidence interval).
Tables 3 and 4
Address multiplicity by reporting any other analyses performed, including subgroup analyses and adjusted analyses, indicating those pre-specified and those exploratory.
All important adverse events or side effects in each intervention group
Interpretation of the results, taking into account study hypotheses, sources of potential bias or imprecision and the dangers associated with multiplicity of analyses and outcomes.
General interpretation of the results in the context of current evidence